Reimagining Cancer Care: Ralph Hefti at Siemens Healthineers Executive Summit

As advances in cancer detection and treatment enable more people to live longer with cancer, healthcare systems face a growing challenge: how to deliver personalised, high-quality care at scale while maintaining financial sustainability. 

This was a central theme of a panel session im Siemens Healthineers Executive Summit, held in Frankfurt on 20 October, encompassing the role of innovation, integrated care models and strategic investment in the future of oncology.

Stingray Healthcare Group CEO Ralph Hefti joined fellow panelists Keith Stewart, Director of the Princess Margaret Cancer Center, and Regina Beets-Tan, Member of the Board of Directors for Maastricht Radiation Oncology Institute in the Netherlands.

The discussion explored how healthcare organisations can move beyond individual technological advances to reshape Krebsbehandlung pathways, improve the patient experience and build more sustainable systems across Europe.

The three perspectives from internationally recognised experts in academia and private care framed the conversation: personalising breakthroughs, scaling innovation economically and leading change across the wider healthcare ecosystem.

Personalising cancer care through innovation

Dr Keith Stewart, a physician scientist who has expertise in genomics, precision medicine and innovative cancer therapies, provided his thoughts on which innovations will have the greatest impact on cancer care. 

One important area is risk-based screening. Genomic information can help identify certain individuals who may have an increased risk of developing particular cancers, potentially supporting more targeted surveillance and earlier investigation. 

Treatment innovation is also expanding the options available to patients. Developments in targeted medicines, immunotherapy, precision radiotherapy, minimally invasive surgery and robotic-assisted procedures are changing how some cancers are managed.

The objective is not simply to introduce more advanced technologies. It is to identify the most appropriate combination of interventions for each patient, taking account of tumour characteristics, clinical evidence, potential adverse effects and individual circumstances.

Transforming the radiotherapy experience

Next, the discussion focused on the innovations in radiotherapy for cancer care, with a contribution from Professor Regina Beets-Tan, a member of the Board of Directors of MAASTRO and internationally renowned radiologist.

Professor Beets-Tan’s research focuses on preclinical, translational, and clinical innovations in imaging and AI, with the aim of improving decision-making and the evaluation of treatment  response in cancer. 

Radiotherapy remains an important component of cancer treatment, but conventional treatment pathways can involve repeated hospital visits, careful positioning and substantial demands on patients and healthcare teams.

Professor Beets-Tan explained that technological advances are creating opportunities to improve treatment precision and reduce the time required for selected procedures. 

MAASTRO’s experience with a new radiotherapy approach, recently launched as Accela with NeoArc, provided an example of how innovation could influence both clinical delivery and the patient experience.

The approach aims to deliver treatment in seconds, with the potential to improve precision and reduce treatment-session requirements for appropriately selected patients. 

Depending on the treatment and clinical circumstances, this could mean fewer visits, shorter breath-hold procedures and less time spent travelling to and attending appointments.

Professor Beets-Tan commented that such developments may also create opportunities to assess treatment options for patients whose disease characteristics have previously limited the suitability of certain approaches. 

Oligometastatic disease, in which cancer has spread to a limited number of sites, is one area where carefully selected patients may be considered for targeted local treatments alongside other appropriate therapies.

Scaling innovation while maintaining financial sustainability

For Ralph Hefti, innovation at Stingray Healthcare Group is also an operational and strategic consideration. The group is Europe’s largest independent cancer care platform, with 32 specialist centres across eight countries supporting around 40,000 cancer patients annually. 

Delivering advanced cancer care across a fragmented European healthcare market requires models that can adapt to different national systems while maintaining appropriate clinical standards.

Ralph explained that operational efficiency is one part of this challenge. Better planning, coordinated workflows and appropriate use of technology can help healthcare organisations manage resources and deliver services more effectively. 

Improving efficiency may also create opportunities to expand access to specialist expertise without assuming that every increase in demand must be met through proportional increases in resources.

A second consideration is integration across the cancer care pathway. Fragmented services and disconnected decision-making can make it more difficult to coordinate specialist input and use information effectively.

Stingray’s approach encompasses exploring ways to connect expertise across pathways, including through external tumour boards. 

These forums can support multidisciplinary discussion by bringing together relevant specialists to review complex cases and consider appropriate management options.

When supported by clear governance, secure information exchange and defined responsibilities, such models can help connect expertise across organisational boundaries.

They also demonstrate why innovation in healthcare delivery must encompass organisational structures and clinical collaboration, rather than technology alone.

Connecting data, artificial intelligence and clinical expertise

Professor Beets-Tan was asked for her thoughts on how fully integrated data infrastructure can be ultimately combined with AI to improve outcomes for cancer patients. 

Sie hat das erklärt information from genomics, medical imaging, pathology and treatment records can provide complementary insights into a patient’s disease. 

When these sources can be accessed and interpreted appropriately, they may support more informed decisions about risk, diagnosis, treatment selection and follow-up.

AI could contribute to this process by supporting image analysis, risk assessment, treatment planning and the evaluation of likely treatment responses. 

It may also help identify opportunities to reduce unnecessary investigations or interventions, provided that these applications are clinically validated and used within appropriate governance frameworks.

For a European oncology network, cross-border collaboration offers opportunities to share expertise and develop more connected approaches to care. 

Realising these opportunities requires compliance with applicable Datenschutzanforderungen, appropriate clinical oversight and careful evaluation of performance across different patient populations.

Funding a more connected cancer care ecosystem

Delivering these ambitions requires sustainable investment. Healthcare budgets remain constrained, while the costs of specialist infrastructure, workforce development, research and new technologies can be substantial.

Dr Stewart explained that clinical trials can provide an important route for evaluating emerging treatments and supporting innovation. 

They may also attract research investment and create opportunities for collaboration between healthcare organisations, academic institutions and industry partners.

Public-private partnerships and philanthropic funding can provide additional mechanisms for supporting research, infrastructure and service development. 

Investment in prevention and early detection also deserves consideration, although its value depends on the intervention, implementation costs and measurable outcomes over time.

Stronger collaboration between healthcare providers, researchers, policymakers and industry can help align investment with clearly defined clinical needs and sustainable delivery models.

Leading change towards sustainable, patient-centred cancer care

The conference discussion highlighted a central principle: advances in cancer treatment must be matched by changes in how healthcare systems organise, finance and deliver care. 

Centres of Excellence can play an important role in this approach by bringing together Fachkompetenz, advanced technologies, multidisciplinary collaboration and established clinical governance. 

The long-term ambition is to support a future in which more cancers can be prevented or detected early, treatment is increasingly tailored to individual circumstances, and people living with cancer can access coordinated, appropriate care throughout their lives.

Mehr über erfahren Stingray Healthcare Group and its approach to oncology innovation, specialist collaboration and patient-centred cancer care across Europe.

0 Antworten

Schreiben Sie bitte einen Kommentar.

Möchten Sie in die Diskussion?
Fühlen Sie sich frei zu tragen!

Schreiben Sie bitte einen Kommentar.